SML3213

Lobaplatin

≥98% (NMR)

• Synonym(e): Cis-[trans-1,2-cyclobutanebis(methylamine)-N,N′]-[(2S)-lactate-O1,O2)-platinum (II), D 19466, D-19466, D19466, [rel-(1R,2R)-1,2-cyclobutanedimethanamine-κN,kN′][(2S)-2-(hydroxy-kO)propanoato(2-)-kO]-, (SP-4-3)-platinum, trans-1,2-Cyclobutanedimethanamine, platinum complex
• Empirische Formel (Hill-System): C₉H₁₈N₂O₃Pt
• CAS-Nummer: 135558-11-1
• Molekulargewicht: 397.33
• NACRES: NA.77
• UNSPSC Code: 12352107
• Assay: ≥98% (NMR)
• Form: powder

Eigenschaften

• Quality Segment: 100
• assay: ≥98% (NMR)
• form: powder
• color: white to beige
• solubility: H₂O: 2 mg/mL, clear (Warmed)
• storage temp.: −20°C
• SMILES string: O=C1[O-][Pt+2]2(N[CH2]C3CCC3CN2)[O-]C1C
• InChI: 1S/C6H12N2.C3H5O3.Pt/c7-3-5-1-2-6(5)4-8;1-2(4)3(5)6;/h5-8H,1-4H2;2H,1H3,(H,5,6);/q-2;-1;+4/p-1/t;2-;/m.0./s1
• InChI key: HADHSETVEMCBPU-TYOUJGAFSA-M

Beschreibung

Biochem/physiol Actions

Lobaplatin (D-19466) is a third-generation platinum anticancer agent in vitro and in vivo, consisting of ~50:50 mixture of the two trans-1,2-cyclobutanedimethanamine diastereomers in complex with L-lactic acid. Llobaplatin shows antitumor efficacy against various human cancer cancer xenografts and significantly prolongs the survival of mice bearing P388 leukemia (mean life span increase post single i.p. in mg/kg = 46%/4.64 & 77/14.7). Compared to first and second generation platinum compounds, lobaplatin appears to be more stable, less toxic, have a better therapeutic index and may overcome tumor resistance.

Third-generation platinum anticancer agent in vitro and in vivo.

Sicherheitshinweise

• Lagerklasse: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable